Go to article: Home | Lula’s progress plan for Brazil: A year onGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: XylemGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: phasetwoGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DepthGo to article: Lula’s progress plan for Brazil: A year on Go to article: How sham patents are hurting the pharma industryGo to article: Tracking the opioid lawsuit settlements amidst calls for oversight Go to article: Cell and gene therapy landscape in the USGo to article: Q&A: Cell and gene therapy value assessments need a rework to allow access Go to article: Pharmaceutical discovery through a gravitational lens Go to article: Thematic Take: ESGGo to article: Thematic Take: contentsGo to article: Foreword: A growing sense of urgency in ESG Go to article: ESG 1.0 is over – get ready for ESG 2.0 Go to article: ESG becomes mandatory: how to prepareGo to article: Theme timeline: the past, present and future of ESG Go to article: Net-zero strategies for the pharma sector Go to article: Leading pharma companies and initiatives in the race for net zeroGo to article: GlobalData’s Christopher Papadopoullos on net-zero strategy for businesses Go to article: 38% of companies lack an ESG strategy – GlobalData survey Go to article: Sustainability challenges in rare disease trials remain, but change is happeningGo to article: ESCMID 2024: The infectious consequences of climate change Go to article: Bring your own device: How patients own tech is being used in clinical trialsGo to article: Can pharma overcome generative AI’s bias problem?Go to article: China-US tensions are spilling into the biotech sector Go to article: Japanese patients among least empowered in the developed worldGo to article: World Air Quality Report: what are the health impacts and where is it worst? Go to article: Why has New Zealand U-turned on the world’s first smoking ban?Go to article: Microplastics in placentas: how serious is the problem? Go to article: Deal activity related to ESG in the pharma industry since 2021Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: BEA TechnologiesGo to article: CytivaGo to article: ListingsGo to article: EventsGo to article: Innovation RankingsGo to article: Buyer's GuidesGo to article: Next issue